John Mitrofanis

What is he best known for?

The fields of study he is best known for:

• Neuroscience
• Internal medicine
• Neuron

John Mitrofanis focuses on Neuroscience, Anatomy, Zona incerta, Parkinson's disease and Nucleus. His Neuroscience study frequently involves adjacent topics like Subthalamic nucleus. His studies deal with areas such as Retina and Cell biology as well as Anatomy.

He has included themes like Sensory system and Diencephalon in his Zona incerta study. The Parkinson's disease study which covers Neuroprotection that intersects with Anesthesia, Tyrosine hydroxylase and Endocrinology. His Substantia nigra research focuses on subjects like Pharmacology, which are linked to Pars compacta.

His most cited work include:

• Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease (923 citations)
• Some certainty for the "zone of uncertainty"? Exploring the function of the zona incerta. (179 citations)
• Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys (178 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Neuroscience, Anatomy, MPTP, Substantia nigra and Internal medicine. John Mitrofanis studied Neuroscience and Deep brain stimulation that intersect with Adverse effect. John Mitrofanis has researched Anatomy in several fields, including Retina and Brainstem.

His work is dedicated to discovering how MPTP, Neuroprotection are connected with Parkinson's disease, Pathology and Neurotoxin and other disciplines. His research integrates issues of Stereology and Gliosis in his study of Substantia nigra. His study in Endocrinology extends to Internal medicine with its themes.

He most often published in these fields:

• Neuroscience (58.20%)
• Anatomy (27.05%)
• MPTP (33.61%)

What were the highlights of his more recent work (between 2016-2021)?

• Neuroscience (58.20%)
• Parkinson's disease (21.31%)
• Neuroprotection (24.59%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Neuroscience, Parkinson's disease, Neuroprotection, Disease and MPTP. His Neuroscience study is mostly concerned with Striatum, Putamen, Dopaminergic Cell, Tyrosine hydroxylase and Default mode network. His Striatum research incorporates themes from Basal ganglia, Dopaminergic and Midbrain.

His research on Tyrosine hydroxylase often connects related topics like Substantia nigra. His Parkinson's disease research incorporates elements of Sound, Physical medicine and rehabilitation and MEDLINE. His MPTP research is multidisciplinary, incorporating perspectives in Neurotoxin, Pharmacology and Pars compacta.

Between 2016 and 2021, his most popular works were:

• Photobiomodulation-induced changes in a monkey model of Parkinson’s disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum (15 citations)
• Acquired Resilience: An Evolved System of Tissue Protection in Mammals. (13 citations)
• The behavioural and neuroprotective outcomes when 670nm and 810nm near infrared light are applied together in MPTP-treated mice. (13 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Neuron
• Neuroscience

John Mitrofanis mostly deals with Neuroscience, Dopaminergic Cell, MPTP, Tyrosine hydroxylase and Substantia nigra. His work carried out in the field of Neuroscience brings together such families of science as Internal medicine and Cerebral blood flow. His Dopaminergic Cell research is multidisciplinary, incorporating elements of Striatum, Neurology, Parenchyma and Macaque.

The various areas that he examines in his MPTP study include Stereology, Neuroprotection, Pharmacology and Pars compacta. His Tyrosine hydroxylase research is multidisciplinary, relying on both Dopaminergic, Tyrosine hydroxylase immunohistochemistry and Midbrain. His Substantia nigra study combines topics from a wide range of disciplines, such as Basal ganglia, Gliosis, Parvalbumin and Neuroglia.